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Background: Atrial septal defect (ASD) is one of the most common congenital heart diseases. 
Percutaneous closure is the preferred treatment, but certain complications remain a concern. The 
most common devices are AMPLATZER™ (ASO) (St. Jude Medical, St. Paul, MN, USA) and 
Figulla Flex® septal occluders (FSO) (Occlutech GmbH, Jena, Germany). The present study 
aimed to assess main differences in outcomes.  
Methods: A systematic search in Pubmed and Google scholarship was performed by two 
independent reviewers for any study comparing ASO and FSO. Searched terms were “Figulla”, 
“Amplatzer”, and “atrial septal defect”. A random-effects model was used. 
Results: A total of 11 studies including 1770 patients (897 ASO; 873 FSO) were gathered. 
Baseline clinical and echocardiographic characteristics were comparable although septal 
aneurysm was more often reported in patients treated with ASO (32% vs. 25%; p = 0.061). 
Success rate (94% vs. 95%; OR: 0.81; 95% CI: 0.38–1.71; p = 0.58) and peri-procedural 
complications were comparable. Procedures were shorter, requiring less fluoroscopy time with 
an FSO device (OR: 0.59; 95% CI: 0.20–0.97; p = 0.003). Although the global rate of 
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complications in long-term was similar, the ASO device was associated with a higher rate of 
supraventricular arrhythmias (14.7% vs. 7.8%, p = 0.009). 
Conclusions: Percutaneous closure of ASD is a safe and effective, irrespective of the type of 
device. No differences exist regarding procedural success between the ASO and FSO devices but 
the last was associated to shorter procedure time, less radiation, and lower rate of 
supraventricular arrhythmias in follow-up. Late cardiac perforation did not occur and death in the 
follow-up was exceptional. 




Atrial septal defect (ASD) is one of the most common congenital cardiac diseases 
representing up to 8% of them. As a main type, the therapeutic management of ostium secundum 
ASD has quickly evolved from surgery to percutaneous closure despite the low mortality rate (< 
1%) of surgical repair. This can be explained by the good results of percutaneous closure through 
a less invasive procedure. Since first percutaneous closure of an ASD was performed more than 
four decades ago [1–3], and different devices have been proved to be safe and effective. In the 
last decade, the most commonly used ASD closure devices include the Amplatzer Septal 
Occluder (ASO) (Abbott Vascular®, California, USA) and the more recent Figulla Flex septal 
occluder (FSO) (Occlutech® GmbH, Jena, Germany). The last has been developed in order to 
minimize complications while maintaining efficacy. However, comparisons of this device with 
those representing a broader experience is limited to a short series and potential advantages of 
the newer devices remain unproven. This is of major interest given the current investigations 
focused on bioresorbable closure devices that will require comparison with quality standards.  
 The Amplatzer Septal Occluder (Fig. 1A) is composed of a nitinol metal wire 
mesh that holds two self-expanding discs, and can be steadily deployed and recaptured [4, 5]. 
Dacron patches with a pro-coagulant material have been placed within the mesh in order to 
promote thrombosis and endothelialization [3–5]. Concerns with this device include those related 
to the procedure as embolization or residual shunt, and the rare but worrisome risk of tissular 
erosion/perforation in the long term. The newer Figulla Flex device (Fig. 1B, C) aims to diminish 
the risk of these complications through a less heavy mesh theoretically providing greater 
flexibility with less aggression to the tissues, and its deliverability in mainly larger defects is 
simplified. Also, the lack of a micro-screw potentially allows a smooth delivery and decreases 
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the risk of clot formation [1, 4]. As was said, large prospective randomized studies have not been 
performed to explore these aspects. Hence, the aim herein was to compare the FSO and ASO 
devices in current cohorts through a meta-analysis in order to determine rates of success, as well 
as short- and long-term complications which each system. 
 
MATERIALS AND METHODS 
Literature search strategy 
A systematic review of all published research in PubMed and Google-Scholar databases 
between February/2009 and February/2018 regarding percutaneous closure of ASDs was 
independently performed by two authors (AA and IJAS). The following terms were used: 
“Figulla”, “Amplatzer”, and “atrial septal defect” (Fig. 20. Only full English peer-reviewed 
articles were selected and editorials or expert opinions were ruled out. Discrepancies between 
reviewers were resolved by discussion, and a consensus was reached.  
 
Eligibility criteria 
Eligible studies were considered those directly comparing outcomes of patients receiving 
either ASO or FSO closure devices and reporting peri-procedural and long-term outcomes. 
Events were entered as zeros in the tables for those studies that reported no complications during 
the follow-up period.  
 
Main outcomes 
Primary outcomes were procedural success, peri-procedural, and long-term 
complications. The last included cardiac perforation, cardiac death (including those of unknown 
origin), neurological events, and thrombus formation at any time point. Long-term was 
considered to be at least 6 months of follow-up.  
 
Statistical analysis 
Qualitative variables are expressed as an absolute frequency and percentage. Continuous 
variables are expressed as mean ± standard deviation unless otherwise specified. In order to 
compare demographic variables and risk factors between groups, the χ2 or the Fisher test were 
used for categorical variables and the Student-t test for continuous variables in cases where it 
was required. 
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 Potential publication bias was assessed by using a funnel plot. As a measure of the 
combined effect for the studies included, the odds ratio (OR) was estimated, valid for prospective 
and retrospective studies. The confidence interval was at 95%, as well as its statistical 
significance. The homogeneity between studies was contrasted by the QH statistic. In regard to 
the low sensitivity of this test, p < 0.10 values were considered as significant. To overcome this 
limitation in some way, the I2 statistic was estimated as well, which measures the proportion of 
the total variation of the studies explained by the heterogeneity and its 95% confidence interval 
(CI). A random effects model was used for those cases in which the I2 statistic was greater than 
50% and the model of fixed effects for opposite cases. A random effects model was used for all 
outcomes to obtain a loose estimate due to the inclusion of prospective and retrospective studies. 
All p values were two sided. All analyses were conducted using the statistical software 
Review Manager 5.3. 
 
RESULTS 
Patient distribution and baseline characteristics. 
A total of 1827 patients from 11 different studies (Suppl. Table 1) [6–16] underwent 
percutaneous ASD closure, with ASO (n = 897, 49.1%) or FSO (n = 873, 47.8%). Additionally, 
57 patients (3.1% from the global study population) were excluded from the final analyses 
because a different device was used.  
Baseline characteristics of the study population are summarized in Table 1. Age and 
gender were similar between treatment groups with a higher proportion of women (60% vs. 40%, 
p = 0.154). There were no statically significant differences regarding cardiovascular risk factors, 
except for a higher incidence of hypertension (29% vs. 19%; p = 0.004) and smoking (20% vs. 
10%; p = 0.004) in patients treated with ASO. The rate of neurovascular events was very similar 
across both groups. No other differences were found. 
 
Screening protocol and peri-procedural characteristics 
Prior to the percutaneous procedure, patients underwent screening with 
transthoracic/transesophageal echocardiography in all cases. Screening protocols ruled out 
associated neurovascular, hematological or other conditions. During the pre-procedural 
evaluation, the presence of atrial septal aneurysm (ASA) was more often detected in patients 
treated with ASO (32% vs. 25%; p = 0.061). 
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Overall, success rate was comparable (94% for ASO vs. 95% for FSO; OR: 0.81; 95% 
CI: 0.38–1.71; p = 0.58) irrespective of its use for PFO or ASD, but shorter procedure and 
fluoroscopy times were obtained with the FSO device (OR: 0.59; 95% CI: 0.20–0.97; p = 0.003) 
despite similar device size (Fig. 3; Suppl. Figs. 1, 2). General anesthesia was the preferred 
strategy for both devices. 
 
Periprocedural complications 
No differences were found regarding the rate of failed closure or device embolization 
(0.04% vs. 0.1%, p = 0.337) but the absolute rate of residual shunt after the procedure was higher 
in patients treated with ASO than with FSO (12.2% vs. 9%; p = 0.075). The incidence of main 
complications is summarized in Table 1.  
One procedural-related death due to cardiac perforation during balloon sizing was 
reported though the patient died two months later as a result of other hospitalization-related 
complications. Also, one transient ischemic event occurred a few minutes after ASD closure. 
Finally, one case of coronary embolism, and two of device thrombosis were also reported.  
A pooled analysis of all procedural related complications (including cardiac perforation, 
device embolization, device thrombosis, severe arrhythmias, vascular complication, neurological 
events, and coronary embolism) was performed demonstrating the lack of statistical difference 
between both devices. 
 
Follow-up outcomes. 
Follow-up data were reported in all the articles. The mean follow-up for the global study 
population was 10.7 ± 6.9 months. Main complications within this period are summarized in 
Table 1. Post-procedural differences in the rate of residual shunt did not persist in the follow-up 
(8.5% vs. 9.3%, OR: 1.04; 95% CI: 0.60–1.79; p = 0.89) as depicted in Figure 3. However, the 
rate of supraventricular arrhythmia + atrial fibrillation was significantly higher after ASO 
(14.7%) than after FSO (7.8%, p = 0.009) in the pooled analysis. This statistical difference did 
not persist when a separate analysis was performed for PFO and ASD patients but a trend 
persisted in PFO cases and absolute values of this complication remained higher in patients 
harboring ASO devices (Suppl. Table 2). 
The most frequent severe complication in long-term was recurrent neurovascular event 
including three cases of transient ischemic attack and one case of stroke. None who presented 
adhered thrombi to the device but, on the contrary, in half of them a residual shunt was present 
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requiring surgical closure [10]. Four cases of device thrombosis were observed, one of them was 
noted at 12 months after the intervention, which required surgical removal [10]; the other 3 cases 
presenting this complication, despite continued dual antiplatelet therapy and was successfully 
managed with intravenous heparin and oral anticoagulation [11]. One case of infective 
endocarditis due to Staphylococcus lugdunensis was reported 3 months after device placement, 
had positive blood cultures but no vegetation on the device as assessed by transesophageal 
echocardiography, and infection resolved after antibiotic treatment [7]. None of the studies 
reported any death or other major complication such as aortic erosion or device fracture in 
follow-up. 
Regarding the antithrombotic strategy 6 studies reported the use of intravenous heparin 
during the procedure and, afterwards, 4 studies recommended transitory dual antiplatelet therapy 
(acetylsalicylic acid [ASA] + clopidogrel) whereas single antiplatelet therapy with ASA was 
preferred in 4 more studies. Prophylaxis of endocarditis was recommended for up to 6 months. 
 
DISCUSSION 
Percutaneous closure of ostium secundum ASD has become the standard care over the 
last decades [17–20]. Currently, alternative devices can be used in this scenario with ASO and 
FSO being the preferred ones. Notwithstanding this, large comparative studies of these 
technologies remain lacking. This meta-analysis demonstrated that, in similar populations, both 
devices present comparable success rates (≥ 97% for both) and also a similar rate of main 
procedural-related complications including imaging findings such as residual shunt (~9% at 1-
year follow up) or device thrombosis. However, procedures where shorter with FSO suggesting a 
simpler delivery process, requiring less radiation which is a sensitive aspect in this young target 
population, and they also presented with half the rate of supraventricular arrhythmias in follow-
up which might be explained by the properties of the FSO device with a less heavy mesh, likely 
diminishing the interaction with atrial tissue.  
 
Baseline risk and post-procedural main complications 
There was a higher prevalence of septal aneurysm among patients that underwent closure 
with ASO devices (32% vs. 25%, p = 0.061) which might partially explain the greater residual 
shunt detected with ASO in the peri-procedural transesophageal echocardiography. Pre-
procedural screening and diagnosis of septal anomalies with transesophageal echocardiography 
has demonstrated an excellent specificity to diagnose and measure interatrial shunts [21–23] but 
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also might be useful in determining which device is optimal for each patient. According to the 
present findings, those patients with baseline risk of residual shunt (i.e. larger defects, septal 
aneurysm) and those predisposed to supraventricular arrhythmias (i.e. larger atria or history of 
paroxysmal atrial fibrillation) might benefit more from a smoother device. 
Percutaneous closure of the septal defects presented similar success rates to those 
reported in former studies (96–98%) [24]. The procedure is considered successful even in the 
presence of a mild residual shunt if the device is stable though it is well known that mild to 
moderate residual shunts might preclude from full endothelialization [5]. Indeed, current 
evaluation of residual shunting degree is based on the classification by Boutin et al. [24] (mild 1–
2 mm, moderate 2–4 mm, and large 4–8 mm) which might present certain limitations when 
evaluating the impact on long-term outcomes. Although percutaneous closure presents a lower 
rate of complications as compared to surgical closure (7% vs. 24%), the presence of residual 
shunt and its associated risks (right heart overload, paradoxical emboli, supraventricular 
arrhythmia, etc.) might require surgical closure more often than thought. On the other hand, the 
absence of cases presenting cardiac erosion in this research is a reassuring finding but since that 
might appear even years after the procedure [24, 25] and is a life-threatening complication, any 
measure aimed to diminish that risk, as is the use of more flexible devices, ought to be 
considered [26]. 
Finally, the development of supraventricular arrhythmia is a classical concern in patients 
suffering from left-to-right blood shunting but, paradoxically, sometimes they can be triggered 
by the percutaneous closure device itself, likely due to local inflammation and scarring. In this 
regard, the potential variable impact of devices manufactured with different raw materials might 
explain the lower rate of this complication with the FSO [27, 28]. It is noted, this difference in 
the rate of supraventricular arrhythmias were not statistically significant when analyzed 
separately for PFO and congenital ASD but the persistence of a statistical trend also supports that 
this hypothesis which merits further investigation. 
 
Uncommon complications: endocarditis, devices thrombosis and neurovascular events 
Device implantation is performed under strict asepsia and with prior antibiotic 
prophylaxis [29] to lower the risk of device related infective endocarditis. However, this 
complication is occasionally reported in the literature [30]. Consensus has not been reached 
regarding adequate antibiotic prophylactic treatment but some authors suggest up to 6 months 
until endothelialization is completed (according to findings from animal models) [26], but also, 
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the raw materials and structure of the devices might play a role. Similarly, device thrombosis is 
rare but could be additionally associated to the use of one material or another and its structure. 
However, more data are needed to verify this hypothesis since no differences were found in this 
research. Finally, neurovascular events have been related to the presence of residual shunts [27, 
28] which was not uncommon in this analysis and should raise attention to the most adequate 
imaging tool to be used in follow-up and also stresses the importance of adequate sizing during 
the procedure; the use of ASO or FSO neither played a role on this complication and both were 
equally safe in this regard. 
There are a number of limitations related to this work. First, the paucity of multicentric 
randomized studies and the typology of the compiled studies may somehow limit the external 
validity of the reported findings. Secondly, outcomes were reported only for up to 1 year but 
longer follow-up would be required to assess safety issues of concern. Finally, some of the 
gathered studies presented a lack of clear definition of major and minor complications and their 
underreporting could not be ruled out. Also, some of the studies had small sample sizes which 
may have had an impact on the results due to low operator experience with percutaneous closure 
of interatrial septal defects.  
 
CONCLUSIONS 
In this meta-analysis that included 11 non-randomized studies and > 1800 patients 
undergoing ASD closure with both, the ASO or the FSO closure devices, safety and 
effectiveness were similar as well as global success rate. However, procedures were shorter with 
the FSO device and the rate of supraventricular arrhythmias in follow-up was lower. Importantly, 
no cases of late cardiac erosion were detected. Newer bioresorbable devices will need to 
demonstrate competitive results to those herein reported.  
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Table 1. Reported baseline characteristics, procedural and follow-up outcomes. 
Variables Global study 
population 
N = 1827 
Amplatzer  
N = 897/1770 
(50.7%) 
Figulla 




Females 663/1099 (60%) 350 (62%) 313 (58%) 0.154 
Age [years] 45.48 ± 10.39 44.08 ± 11.48 47.02 ± 9.08 < 0.001 
Hypertension 149/634 (24%) 85/297 (29%) 64/337 (19%) 0.004 
Diabetes 15/634 (24%) 9/297 (3%) 6/337 (2%) 0.301 
Dyslipemia  144/493 (29%) 66/225 (29%) 78/268 (29%) 0.956 
Smoking 72/493 (15%) 44/225 (20%) 28/268 (10%) 0.004 
TIA 411/744 (55%) 193/347 (56%) 218/397 (55%) 0.846 
Stroke 218/634 (34%) 102/297 (34%) 116/337 (34%) 0.983 
Recurrent ischemic or 
embolic events 
222/634 (35%) 105/297 (35%) 117/337 (35%) 0.867 
Thrombophilia 84/594 (14%) 39/277 (14%) 45/317 (14%) 0.995 
Atrial septal aneurysm 186/657 (28%) 96/301 (32%) 90/356 (25%) 0.061 
NYHA III-IV  10/149 (7%) 5/72 (7%) 5/77 (6%) 0.999 
Procedural outcomes 
Procedural success 788/809 (97.4%) 435/446 (98%) 353/363 (97%) 0.8 
Procedural time [min] 40.59 ± 25.25 41.82 ± 22.54 39.24 ± 27.94 0.166 
Fluoroscopic time [min] 11.60 ± 20.05 12.22 ± 19.42 10.91 ± 20.73 < 0.001 
Device size [mm] 21.18 ± 4.23 21.19 ± 3.87 21.16 ± 4.65 0.37 
Device embolization 9/1683 (0.53%) 3/848 (0.4%) 6/826 (1%) 0.337 
Vascular complication 9/908 (1%) 4/441 (0.9%) 5/458 (1.1%) 0.999 
Residual shunt 131/1287 (10.2%) 46/373 (12.2%) 54/386 (9%) 0.075 
Stroke/TIA  1/1770 (0.05%) 0 1/873 (0.1%) 0.999 
Device thrombosis  0 0 0 0.999 
Coronary embolism  1/101 (1%) 1/52 (2%) 0 0.999 
Death  1/445 (0.2%) 1/445 (0.2%) 0/463 0.999 
Follow up outcomes 
  12 
Death  0 0 0 – 
Aortic erosion  0 0 0 – 
Device fracture  0 0 0 – 
Stroke/TIA 5/788 (0.6%) 2/251 (0.8%) 3/296 (1%) 0.999 
Endocarditis 1/788 (0.1%) 0 1/296 0.999 
Residual shunt (at 6–12 
months) 
70/788 (8.79%) 17/222 (7.7%) 17/160 (10.6%) 0.31 
SVA and AF 60/547 (11%) 37/251 (14.7%) 23/296 (7.8%) 0.009 
SVA  50/406 (12.3%) 30/179 (16.8%) 20/227 (8.8%) 0.006 
AF  10/547 (1.8%) 7/251 (2.8%) 3/296 (1%) 0.198 
AF — atrial fibrillation; NYHA — New York Heart Association; SVA — supraventricular 
arrhythmia; TIA — transient ischemic attack 
 
Figure 1. Amplatzer septal occluder (A) and Figulla Flex II (B, C) showing main differential 
features of Figulla Flex including the lack of screw attachment (replaced by a ball, B) and the 
smooth left atrial disc (C). 
 
Figure 2. Flow chart showing search results and selection of the studies included in the meta-
analysis. 
 
Figure 3. Forest plot reflecting procedural and follow-up outcomes of the patients included in 
the meta-analysis. *Vertical line represents “no difference” point between the Amplatzer and 
Figulla groups; Horizontal lines 95% confidence interval (CI). Squares represent odds ratio for 
each study (the size of each square denotes the proportion of information given by each study). 
Diamonds represent pooled odds ratios from all studies.  
 



